<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40937414</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1664-2392</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in endocrinology</Title><ISOAbbreviation>Front Endocrinol (Lausanne)</ISOAbbreviation></Journal><ArticleTitle>Emerging perspectives on once-weekly insulins in type 1 and type 2 diabetes: a mini-review.</ArticleTitle><Pagination><StartPage>1656884</StartPage><MedlinePgn>1656884</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1656884</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fendo.2025.1656884</ELocationID><Abstract><AbstractText>The development of once-weekly basal insulin analogues, such as insulin icodec and efsitora alfa, represents a promising strategy to reduce injection burden and improve adherence in diabetes management. This mini-review summarizes the recent findings from clinical trials evaluating once-weekly insulin therapies in both type 1 and type 2 diabetes. In type 1 diabetes, available data remain limited; however, the ONWARDS 6 and QWINT-5 trials demonstrated that once-weekly icodec and efsitora, respectively, achieved comparable reductions in HbA1c to once-daily insulin degludec, when used in combination with prandial insulin. In type 2 diabetes, accumulating evidences from randomized clinical trials supports the efficacy of once-weekly icodec and efsitora, showing non-inferiority-and in some cases, superiority-compared to once-daily basal insulin, both in insulin-na&#xef;ve individuals and in those previously treated with insulin. Safety profiles of once-weekly insulins in type 2 diabetes are reassuring, with similar rates of clinically significant and severe hypoglycemia compared to once-daily regimens. In contrast, trials in type 1 diabetes reported higher hypoglycemia rates with once-weekly insulins. Recent findings from the COMBINE program demonstrated that the fixed-ratio combination of icodec and semaglutide (IcoSema) produced superior HbA1c reductions compared to either agent alone, though not superior to a basal-bolus regimen with glargine and aspart insulin. However, several important questions remain to be addressed regarding once-weekly insulins, including their long-term efficacy on cardiovascular outcomes and overall long-term safety.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Denimal.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Denimal</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Universit&#xe9; Bourgogne Europe, CHU Dijon Bourgogne, Department of Clinical Biochemistry, INSERM, CTM UMR 1231, PADYS team, Dijon,&#xa0;France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Endocrinol (Lausanne)</MedlineTA><NlmUniqueID>101555782</NlmUniqueID><ISSNLinking>1664-2392</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D049528">Insulin, Long-Acting</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049528" MajorTopicYN="N">Insulin, Long-Acting</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">diabetes mellitus</Keyword><Keyword MajorTopicYN="N">glycemic control</Keyword><Keyword MajorTopicYN="N">insulin efsitora</Keyword><Keyword MajorTopicYN="N">insulin icodec</Keyword><Keyword MajorTopicYN="N">long-acting insulin</Keyword></KeywordList><CoiStatement>The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40937414</ArticleId><ArticleId IdType="pmc">PMC12420296</ArticleId><ArticleId IdType="doi">10.3389/fendo.2025.1656884</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gentile S, Strollo F, Viazzi F, Russo G, Piscitelli P, Ceriello A, et al. Five-year predictors of insulin initiation in people with type 2 diabetes under real-life conditions. J Diabetes Res. (2018) 2018:7153087. doi:&#xa0; 10.1155/2018/7153087, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/7153087</ArticleId><ArticleId IdType="pmc">PMC6169213</ArticleId><ArticleId IdType="pubmed">30327785</ArticleId></ArticleIdList></Reference><Reference><Citation>Gald&#xf3;n Sanz-Pastor A, Justel Enr&#xed;quez A, S&#xe1;nchez Bao A, Ampudia-Blasco FJ. Current barriers to initiating insulin therapy in individuals with type 2 diabetes. Front Endocrinol. (2024) 15:1366368. doi:&#xa0; 10.3389/fendo.2024.1366368, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2024.1366368</ArticleId><ArticleId IdType="pmc">PMC10979640</ArticleId><ArticleId IdType="pubmed">38559691</ArticleId></ArticleIdList></Reference><Reference><Citation>Wysham C, Bajaj HS, Del Prato S, Franco DR, Kiyosue A, Dahl D, et al. Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment. N Engl J Med. (2024) 391:2201&#x2013;11. doi:&#xa0; 10.1056/NEJMoa2403953, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2403953</ArticleId><ArticleId IdType="pubmed">39254740</ArticleId></ArticleIdList></Reference><Reference><Citation>Philis-Tsimikas A, Bergenstal RM, Bailey TS, Jinnouchi H, Thrasher JR, Ilag L, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial. Lancet. (2025) 405:2279&#x2013;89. doi:&#xa0; 10.1016/S0140-6736(25)01044-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(25)01044-X</ArticleId><ArticleId IdType="pubmed">40562047</ArticleId></ArticleIdList></Reference><Reference><Citation>Blevins T, Dahl D, P&#xe9;rez Manghi FC, Murthy S, Ortiz Carrasquillo R, Li X, et al. Once-weekly insulin efsitora alfa versus once-daily insulin glargine U100 in adults with type 2 diabetes treated with basal and prandial insulin (QWINT-4): a phase 3, randomised, non-inferiority trial. Lancet. (2025) 405:2290&#x2013;301. doi:&#xa0; 10.1016/S0140-6736(25)01069-4, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(25)01069-4</ArticleId><ArticleId IdType="pubmed">40562048</ArticleId></ArticleIdList></Reference><Reference><Citation>Billings LK, Andreozzi F, Frederiksen M, Gourdy P, Gowda A, Ji L, et al. Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial. Lancet Diabetes Endocrinol. (2025) 13:556&#x2013;67. doi:&#xa0; 10.1016/S2213-8587(25)00052-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(25)00052-X</ArticleId><ArticleId IdType="pubmed">40482670</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, et al. Once&#x2212;weekly IcoSema versus once&#x2212;weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open&#x2212;label, multicentre, treat&#x2212;to&#x2212;target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. (2025) 13:568&#x2013;79. doi:&#xa0; 10.1016/S2213-8587(25)00096-8, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(25)00096-8</ArticleId><ArticleId IdType="pubmed">40482671</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Bailey T, Connery L, Miller E, Desouza C, Wang Q, et al. Weekly fixed-dose insulin efsitora in type 2 diabetes without previous insulin therapy. N Engl J Med. (2025) 393:325&#x2013;35. doi:&#xa0; 10.1056/NEJMoa2502796, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2502796</ArticleId><ArticleId IdType="pubmed">40548694</ArticleId></ArticleIdList></Reference><Reference><Citation>de Oliveira HM, Gallo Ruelas M, Fl&#xe1;vio-Reis VHP, Queiroz I, Cavalcante DVS, Barbosa LM, et al. Degludec insulin versus efsitora insulin in diabetes mellitus management: A systematic review and meta-analysis. J Diabetes Complications. (2025) 39:109115. doi:&#xa0; 10.1016/j.jdiacomp.2025.109115, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jdiacomp.2025.109115</ArticleId><ArticleId IdType="pubmed">40627908</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay I, Asong M, Desouza C, Gourdy P, Kar S, Vianna A, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: the ONWARDS 3 randomized clinical trial. JAMA. (2023) 330:228&#x2013;37. doi:&#xa0; 10.1001/jama.2023.11313, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2023.11313</ArticleId><ArticleId IdType="pmc">PMC10354685</ArticleId><ArticleId IdType="pubmed">37354562</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj HS, Aberle J, Davies M, Donatsky AM, Frederiksen M, Yavuz DG, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): A randomized trial. Ann Intern Med. (2023) 176:1476&#x2013;85. doi:&#xa0; 10.7326/M23-1288, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1288</ArticleId><ArticleId IdType="pubmed">37748181</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Bain SC, Gowda A, J&#xf3;dar E, Liang B, Lingvay I, et al. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. N Engl J Med. (2023) 389:297&#x2013;308. doi:&#xa0; 10.1056/NEJMoa2303208, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2303208</ArticleId><ArticleId IdType="pubmed">37356066</ArticleId></ArticleIdList></Reference><Reference><Citation>Philis-Tsimikas A, Asong M, Franek E, Jia T, Rosenstock J, Stachlewska K, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. (2023) 11:414&#x2013;25. doi:&#xa0; 10.1016/S2213-8587(23)00093-1, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00093-1</ArticleId><ArticleId IdType="pubmed">37148899</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu C, &#xc1;sbj&#xf6;rnsd&#xf3;ttir B, Bajaj HS, Lane W, Matos ALSA, Murthy S, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet Lond Engl. (2023) 401:1929&#x2013;40. doi:&#xa0; 10.1016/S0140-6736(23)00520-2, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00520-2</ArticleId><ArticleId IdType="pubmed">37156252</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell-Jones D, Babazono T, Cailleteau R, Engberg S, Irace C, Kjaersgaard MIS, et al. Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet Lond Engl. (2023) 402:1636&#x2013;47. doi:&#xa0; 10.1016/S0140-6736(23)02179-7, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)02179-7</ArticleId><ArticleId IdType="pubmed">37863084</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sourij H, Bracken RM, Carstensen L, Pagliaro Rocha TM, Kehlet Watt S, Philis-Tsimikas A. No evidence of increased hypoglycaemia attributed to physical activity with once-weekly insulin icodec versus once-daily basal insulin degludec in type 1 diabetes: A <i>post hoc</i> analysis of ONWARDS 6. Diabetes Obes Metab. (2025) 27:2882&#x2013;6. doi:&#xa0; 10.1111/dom.16265, PMID: 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.16265</ArticleId><ArticleId IdType="pmc">PMC11965012</ArticleId><ArticleId IdType="pubmed">39972508</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay I, Benamar M, Chen L, Fu A, J&#xf3;dar E, Nishida T, et al. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial. Diabetologia. (2025) 68:739&#x2013;51. doi:&#xa0; 10.1007/s00125-024-06348-5, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00125-024-06348-5</ArticleId><ArticleId IdType="pmc">PMC11950020</ArticleId><ArticleId IdType="pubmed">39820580</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang C, Su R, Wan L, Zhu M, Pu J, Hao C, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of GZR4, a novel once-weekly basal insulin, in healthy participants: A randomized trial. Diabetes Obes Metab. (2025) 27:2515&#x2013;22. doi:&#xa0; 10.1111/dom.16250, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.16250</ArticleId><ArticleId IdType="pubmed">39935080</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazda CM, Bue-Valleskey JM, Chien J, Zhang Q, Chigutsa E, Landschulz W, et al. Novel once-weekly basal insulin fc achieved similar glycemic control with a safety profile comparable to insulin degludec in patients with type 1 diabetes. Diabetes Care. (2023) 46:1052&#x2013;9. doi:&#xa0; 10.2337/dc22-2395, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc22-2395</ArticleId><ArticleId IdType="pmc">PMC10154655</ArticleId><ArticleId IdType="pubmed">36920867</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergenstal RM, Weinstock RS, Mathieu C, Onishi Y, Vijayanagaram V, Katz ML, et al. Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 1 diabetes (QWINT-5): a phase 3 randomised non-inferiority trial. Lancet Lond Engl. (2024) 404:1132&#x2013;42. doi:&#xa0; 10.1016/S0140-6736(24)01804-X, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)01804-X</ArticleId><ArticleId IdType="pubmed">39270686</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenstock J, Bajaj HS, Jane&#x17e; A, Silver R, Begtrup K, Hansen MV, et al. NN1436&#x2013;4383 investigators. Once-weekly insulin for type 2 diabetes without previous insulin treatment. N Engl J Med. (2020) 383:2107&#x2013;16. doi:&#xa0; 10.1056/NEJMoa2022474, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022474</ArticleId><ArticleId IdType="pubmed">32960514</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj HS, Bergenstal RM, Christoffersen A, Davies MJ, Gowda A, Isendahl J, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in type 2 diabetes inadequately controlled on daily basal insulin: a phase 2 randomized controlled trial. Diabetes Care. (2021) 44:1586&#x2013;94. doi:&#xa0; 10.2337/dc20-2877, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2877</ArticleId><ArticleId IdType="pmc">PMC8323191</ArticleId><ArticleId IdType="pubmed">33875485</ArticleId></ArticleIdList></Reference><Reference><Citation>Lingvay I, Buse JB, Franek E, Hansen MV, Koefoed MM, Mathieu C, et al. A randomized, open-label comparison of once-weekly insulin icodec titration strategies versus once-daily insulin glargine U100. Diabetes Care. (2021) 44:1595&#x2013;603. doi:&#xa0; 10.2337/dc20-2878, PMID:</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-2878</ArticleId><ArticleId IdType="pmc">PMC8323172</ArticleId><ArticleId IdType="pubmed">33875484</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>